0.1743
price down icon0.85%   -0.0015
after-market After Hours: .17 -0.0043 -2.47%
loading

Syros Pharmaceuticals Inc Stock (SYRS) Latest News

pulisher
Feb 19, 2025

What Did We Find About Insider Trading At Syros Pharmaceuticals Inc (NASDAQ: SYRS)? - Stocks Register

Feb 19, 2025
pulisher
Feb 17, 2025

StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Feb 17, 2025
pulisher
Feb 10, 2025

Syros Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.17, Down -3.99 - The Dwinnex

Feb 10, 2025
pulisher
Feb 08, 2025

Syros Pharmaceuticals Inc (NASDAQ: SYRS) Now Carries A 12-Month Price Target Of $5. - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 07, 2025

Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation - ACCESS Newswire

Feb 07, 2025
pulisher
Feb 07, 2025

Syros Pharmaceuticals Inc [NASDAQ: SYRS] Sees Increase in Stock Value - Knox Daily

Feb 07, 2025
pulisher
Feb 06, 2025

Check Out Syros Pharmaceuticals Inc (SYRS)’s Trade Data Rather Than the Analysts’ Views - SETE News

Feb 06, 2025
pulisher
Feb 05, 2025

Syros Pharmaceuticals Inc (SYRS) Stock Price and Analyst Predictions - The News Heater

Feb 05, 2025
pulisher
Feb 04, 2025

H.C. Wainwright Upgrades Syros Pharmaceuticals Inc (SYRS) to a Buy from a Neutral - Knox Daily

Feb 04, 2025
pulisher
Feb 03, 2025

Ratio Examination: Syros Pharmaceuticals Inc (SYRS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Feb 03, 2025
pulisher
Feb 01, 2025

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World

Feb 01, 2025
pulisher
Jan 30, 2025

Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World

Jan 30, 2025
pulisher
Jan 28, 2025

Fulcrum Therapeutics (NASDAQ:FULC) versus Syros Pharmaceuticals (NASDAQ:SYRS) Financial Analysis - Defense World

Jan 28, 2025
pulisher
Jan 25, 2025

Syros Pharmaceuticals Inc (NASDAQ: SYRS) Fell -2280.95%, Predicting What To Expect In The Near Future - Marketing Sentinel

Jan 25, 2025
pulisher
Jan 24, 2025

SYRS News Today | Why did Syros Pharmaceuticals stock go down today? - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com - Defense World

Jan 24, 2025
pulisher
Jan 16, 2025

Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Analysts’ Revisions Show Improving Sentiment For Syros Pharmaceuticals Inc (NASDAQ: SYRS) - Stocks Register

Jan 15, 2025
pulisher
Jan 09, 2025

Syros Pharmaceuticals (NASDAQ: SYRS) Receives Notice of Listing Non-ComplianceOn January 6, 2025, Syros Pharmaceuticals, Inc. received deficiency letters from the Nasdaq Stock Market, LLC, highlighting certain non-compliance issues with Nasdaq listi - Defense World

Jan 09, 2025
pulisher
Jan 08, 2025

Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com

Jan 08, 2025
pulisher
Jan 08, 2025

Syros Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Jan 08, 2025
pulisher
Jan 05, 2025

Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World

Jan 05, 2025
pulisher
Dec 30, 2024

November's phase III successes; Syros, Cassava tumble on misses - BioWorld Online

Dec 30, 2024
pulisher
Dec 23, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World

Dec 23, 2024
pulisher
Dec 15, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com India

Dec 15, 2024
pulisher
Dec 11, 2024

JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN

Dec 11, 2024
pulisher
Dec 06, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - The Eastern Progress Online

Dec 06, 2024
pulisher
Dec 04, 2024

Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia

Dec 04, 2024
pulisher
Dec 04, 2024

Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 - Investing.com

Dec 04, 2024
pulisher
Nov 30, 2024

Syros Pharmaceuticals (LTS:0LC7) Enterprise Value : $8.13 Mil (As of Jan. 03, 2025) - GuruFocus.com

Nov 30, 2024
pulisher
Nov 24, 2024

SYRS (Syros Pharmaceuticals) 9-Day RSI : 26.16 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024
pulisher
Nov 23, 2024

Syros cut to neutral by H.C. Wainwright on failed drug study - MSN

Nov 23, 2024
pulisher
Nov 22, 2024

Syros pharmaceuticals chief development officer sells shares for $7,949 - Investing.com India

Nov 22, 2024
pulisher
Nov 21, 2024

Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia

Nov 21, 2024
pulisher
Nov 21, 2024

Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia

Nov 21, 2024
pulisher
Nov 21, 2024

Syros Pharmaceuticals chief legal officer sells $10,320 in stock - Investing.com India

Nov 21, 2024
pulisher
Nov 20, 2024

Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 By Investing.com - Investing.com Canada

Nov 20, 2024
pulisher
Nov 20, 2024

Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com

Nov 20, 2024
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
Cap:     |  Volume (24h):